GMP Grade Peptide Synthesis

Pre-GMP Development

Our manufacturing capabilities are designed to meet actual and future customer needs in respect of

• Synthesis strategy (i.e. solid phase peptide synthesis, solution phase peptide synthesis)
• Chemistry (i.e. Boc-, Fmoc- based synthesis)
• Purification strategy (i.e. preparative HPLC, conventional chromatography, ion exchange, gel chromatography, counter-current distribution)
• Flexibility and upscaling
• Special customer request (i.e. dedicated production lines)
• Special equipment (i.e. enzymatic unit, electrolysis unit)

GMP Production

We manufacture peptides up to 50 amino acids in length and in quantities that can range from gram to multi-kg quantities. Our robust, economical manufacturing processes will help optimize the costs of development. A full range of synthetic technologies are available. The final choice depends on the sequence length, the scale, and the specific project requirements.

Synthesis

• Large-Scale Liquid (Solution) Phase Peptide Synthesis (LPPS)
• Large-Scale Solid Phase Peptide Synthesis (SPPS)
• Large-Scale Hybrid Fragment Synthesis

Peptide Modification

• Acetylation
• Biotin
• Glycosylation
• PEGylation
• Cyclization (Disulfide bonds)

Quality Control

For GMP peptide custom synthesis, we guarantee >98% purity. We provide standard QC tests before releasing GMP products as listed. In addition, extra tests can be provided according to the requests of clients.

Fig. 1 Standard QC tests before releasing GMP products.

Available GMP peptides Synthesis Services

Cell Penetrating Peptides

Multiple antigenic peptides (MAPs)

Cosmetic Peptides

The availability of low-cost active pharmaceutical ingredients from Creative Peptides has had a big impact on the international API manufacturers. Large scale cGMP manufacturing requires a commitment to excellence. Using Creative Peptides as your contract research organization and contract manufacturing organization, you will get more choice, more responsiveness, and more expertise to realize your exciting drug discovery and development support.

References

1. Foster, M., Biancheri, P., Fyfe, M. C., MacDonald, T. T., Rowley, A., Sirohi, S. & Walshe, C. A. (2017). The Pharmacological Profile of TOP1288, a Narrow Spectrum Kinase Inhibitor (NSKI) in Clinical Development as an Anti-Inflammatory Treatment for Ulcerative Colitis. Gastroenterology, 152(5), S766.
2. Anzellotti, A., Cupp, A., & Webster, E. (2018). Sr Scientist. Journal of Nuclear Medicine, 59(supplement 1), 1082-1082.